Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Tekmira Pharmaceuticals Corporation Experiences A Rise In Short Interest

|Includes: Arbutus Biopharma Corp (ABUS)

Tekmira Pharmaceutical Corp has faced a sudden rise in the short interest shares of the company by a massive 24%. The total shares came around at a totality of 82,603 shares by which the increment was recorded. According to the short interest of the company recorded on the 13th February 2015, the shares that were reported by the company at the stock market came around at 3,562,688 shares. As for the estimated daily trading of 548,224 shares, the company has recorded the days to cover at 6.

Of the floated shares, an increment is noted at 17.3% and the total number of interest shares recorded on 30th January 2015, the shares are 3,479,085 in total.

By the end of the trading session on Monday 2nd March 2015, the company had a heated up trade in which the company experienced a loss in the price of the shares. A fall of 0.22 points or 1.2% was observed on the trading counter of Tekmira Pharmaceuticals Corporation and the share price closed at $18.17.

Previously, the shares closed in at a price of $18.39. On Monday, the share price in the start of the session was $18.21 and the lowest point that it touched throughout the session was at a price of $17.5. The trading of the interest shares showed an average of 836,283 shares. The pharmaceutical company has a current market value of $408 million. Presently, the company holds around 22,456,000 shares that are owned by the general public. The company has a 52 week high of $31.48 and a 52 week low of $8.86.

In the past week only, the medicine making company has lost around 8.65% and in the past four weeks, the company has witnessed a loss of 29.05%. As for the S&P 500, the shares have come out to be in a marginal negative position with the loss recorded at 8.4%. The American company has been lately 'underperforming' in the stock index by 32.74% as recorded in the last 4 weeks.

Financial analysts have given guidance and have advised the investors to be cautious about carrying out further trade with the company and to wait for the stock value to increase before selling their shares.

On the other hand, the company is thinking to merge with OnCore Biopharma which is another company that works to create medicines. 99.5% of the shareholders are of the opinion that Tekmira Pharmaceuticals Corporation should merge with the company as this will work out in the both the companies' favor.